watch
Tekla Healthcare Investors

Tekla Healthcare Investors

Sector: Unit Investment Trusts, Face-Amount Certificate Offices, and Closed-End Management Investment Offices Region: MA, United States


: | New York Stock Exchange: HQH


Tekla Healthcare Investors ("HQH") is a diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. HQH primarily invests in the healthcare industry (including biotechnology, medical devices, and pharmaceuticals). The Fund's objective is to provide long-term capital appreciation through investments in companies in the healthcare industry believed to have significant potential for above-average long-term growth. Selection will emphasize the smaller, emerging companies with a maximum of 40% of the Fund's assets in restricted securities of both public and private companies. Management believes this provides a unique opportunity not usually available to mutual fund investors.

Executives

Daniel R. Omstead, Ph.D., President and Chief Executive Officer
Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Timothy Gasperoni, M.B.A, PH.D., Senior Vice President, Research
Dr. Gasperoni joined TCM in March of 2015. Previously, he was a Senior Analyst and Founding Member of Sabby Capital, a public and private equity fund focused on biotechnology and medical devices. Dr. Gasperoni was head of Sabby’s research function and led the firm’s venture investment arm. Previously, Dr. Gasperoni was a Partner and Senior Analyst at Crosswind Investments, LLC, a spin-off of Cowen & Co that managed small- and mid-cap growth funds. During Dr. Gasperoni’s tenure at the firm, the funds outperformed their respective benchmarks by over 2500 basis points. Prior to Crosswind, Dr. Gasperoni was the Senior Analyst at Andesite, LLC, a healthcare-dedicated long-short fund. He led the firm’s research function and was responsible for all syndicate transaction. Prior to his career in financial services, Dr. Gasperoni served in consulting, operating, and scientific roles in the biopharmaceutical industry. Dr. Gasperoni holds a B.A. from Swarthmore College, an M.A. from the University of Pennsylvania, a Ph.D. in Neuroscience from UCLA, and an MBA from MIT. Dr. Gasperoni is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
Christian M. Richard, M.B.A., Senior Vice President, Research
Christian Richard joined TCM in March of 2015. Previously, Mr. Richard was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, Mr. Richard spent almost five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a B.S. in Cellular and Molecular Biology from Purchase College and both an M.S. in Biochemistry and an M.B.A. in Finance from NYU. Mr. Richard is responsible for investment research and due diligence in the biotechnology, medical device, and diagnostic areas and serves as a member of the team responsible for making investments on behalf of the Funds.
Jason C. Akus, MD., Vice President, Research
Jason Akus is responsible for investment research and due diligence in the Medical Device, Diagnostic, and Biopharmaceutical areas. Jason joined TCM in July of 2001 after graduating from Tufts with an M.D. and M.B.A. Jason graduated from Tufts with a B.S. in Mathematics. During medical school, Jason consulted for a variety of Healthcare IT companies.
Laura Woodward, Chief Compliance Officer and Vice President of Fund Administrati
Laura Woodward joined TCM in May 2009 as Chief Compliance Officer and Vice President of Fund Administration. Laura is also Secretary and Treasurer of the Funds. Previously, Laura was a Senior Manager with PricewaterhouseCoopers LLP. Laura is responsible for providing support for and participating in all functions provided by the Adviser to the Funds. Laura is responsible for the administration of the fair valuation process to the extent that the Funds have delegated that duty to the Adviser, certain adviser financial and administrative functions and regulatory compliance matters. Laura is also responsible for developing procedures and policies that are reasonably designed to ensure that the Funds operate in accordance with the Funds’ registration statements. Laura graduated with a B.A. from Lafayette College.
Kolotioloma Silue, Manager of Fund Administration
Kolotioloma Silue joined TCM in August 2010. Before joining TCM, Kolotioloma worked as a Business Analyst and Reporting Specialist with JPMorgan Chase & Co. Kolotioloma also worked at Brown Brothers Harriman & Co. as a Mutual Fund Accounting Supervisor from 2001 until 2008. Kolotioloma is responsible for the accuracy and integrity of the Funds’ custody and accounting records and supporting the Chief Compliance Officer in areas such as financial and regulatory reporting and maintaining the system of internal controls. Kolotioloma responsibilities also include assisting the President with projects as assigned. He holds a B.A. degree in Business Economics from the University of Maine.

News & Analysis